 PARIS and CAMBRIDGE, Mass., April 29, 2021 GLOBE NEWSWIRE -- Biophytis SA Euronext Growth Paris: ALBPS, a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it was granted a non-dilutive funding of 980,000 from the public investment bank BPI Frances DeepTech program, for its MACA program of Macuneos BIO201 in dry Age-Related Macular Degeneration AMD. 